RMD – Deutsche Bank rates the stock as Buy

March quarter results alleviated concerns that growth was slowing in the core sleep business. The company is achieving a benefit from fixed cost leverage, with Deutsche Bank noting EBITDA margin expansion of 106 basis points.

The broker maintains a positive outlook and forecasts 12% growth in earnings per share in FY19-22. Buy rating and US$127 target maintained.

Sector: Health Care Equipment & Services.

Current Price is $15.98. Target price not assessed.

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →